Citizens Memorial Hospital starts giving Kisunla to slow Alzheimer's disease progression скачать в хорошем качестве

Citizens Memorial Hospital starts giving Kisunla to slow Alzheimer's disease progression

Citizens Memorial Hospital's Research Department, led by Neurologist Dr. Curt Schreiber, began donanemab (Kisunla) studies in March 2021, enrolling 15 patients. In September 2024, CMH administered its first infusion of the FDA-approved Alzheimer's drug from that research trial. Kisunla has been shown to reduce amyloid plaques in the brain, which are associated with Alzheimer’s disease. The patient receiving the first infusion of Kisunla at CMH shares about his journey with Alzheimer's and the hope he has for Kisunla to give him more quality time with his family. For more information about research at CMH, visit https://cmhbolivar.info/research.